ViThera develops novel therapeutics for GI diseases based on engineered probiotics and lactic acid bacteria. Our first drug is a novel treatment for IBD.
Sergio Castro, 72, is neither doctor nor priest, but he fills a gap in Mexico’s ragged safety net in health care, accepting no money from his patients, who are mostly Mayans.
Study leads scientists to believe that modifying the bacteria content of the intestines could lessen the risk for lymphoma, and could point way to new therapies.